Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × magrolimab × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6 Gastrointestinal 4 Other solid neoplasm 2 Myeloid 2 Lymphoid 2 Plasma cell 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 216 Paclitaxel 198 Fulvestrant 170 Capecitabine 163 Docetaxel 146 Letrozole 126 pembrolizumab 101 Gemcitabine 87 exemestane 84 Carboplatin 84 Cyclophosphamide 79 palbociclib 74 Anastrozole 71 Lapatinib 70 pertuzumab 68 Bevacizumab 66 130-nm albumin-bound paclitaxel 59 ribociclib 57 eribulin 52 abemaciclib 50 Doxorubicin 48 Vinorelbine 45 Ado-Trastuzumab Emtansine 41 Injections 40 Tamoxifen 39 Albumin-Bound Paclitaxel 39 Everolimus 37 trastuzumab deruxtecan 31 atezolizumab 31 Nivolumab 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04958785 2025-11-04

ELEVATE TNBC

Gilead Sciences

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡